Can I Take Vitamin B6 with Repatha (Evolocumab)?

How Repatha Works and Why Supplements Rarely Affect It

Repatha is a fully human monoclonal IgG2 antibody. It binds the PCSK9 protein and prevents PCSK9 from degrading LDL receptors on hepatocyte surfaces, which keeps more receptors available to clear LDL-C from blood. In the FOURIER trial (N=27,564), evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL and cut major adverse cardiovascular events by 15% over a median 2.2 years [1].

Because evolocumab is a large-molecule biologic, it is not metabolized by cytochrome P450 enzymes in the liver. Small molecules, including most vitamins and dietary supplements, are processed through CYP1A2, CYP2C9, CYP2C19, CYP3A4, and related pathways. Repatha bypasses all of those routes entirely.

Proteolytic Catabolism vs. Hepatic Metabolism

Monoclonal antibodies like evolocumab are broken down by intracellular proteolytic enzymes in a process similar to normal protein digestion. The FDA-approved prescribing information for evolocumab confirms no formal drug interaction studies were conducted for CYP substrates, because the interaction pathway simply does not exist for this class [2].

Vitamin B6 undergoes hepatic phosphorylation to its active coenzyme form, pyridoxal-5-phosphate (PLP). That conversion pathway has zero overlap with PCSK9 biology or IgG catabolism.

What "No Interaction" Actually Means Clinically

Absence of a pharmacokinetic interaction means B6 will not change evolocumab's blood concentration, binding affinity, or half-life of approximately 11 to 17 days. Absence of a pharmacodynamic interaction means B6 does not antagonize or amplify PCSK9 inhibition at the LDL receptor. A 2019 review of monoclonal antibody drug interactions in cardiovascular medicine, published in the Journal of the American College of Cardiology, found no documented supplement-drug interactions for approved PCSK9 inhibitors as a class [3].

Vitamin B6 Physiology and Its Relevance to Cardiovascular Patients

What B6 Does in the Body

Pyridoxal-5-phosphate participates in over 100 enzymatic reactions, most of them involving amino acid transamination and neurotransmitter synthesis. It also serves as a cofactor in the conversion of homocysteine to cystathionine via cystathionine beta-synthase, a reaction that matters to cardiovascular patients because elevated plasma homocysteine is an independent marker associated with increased ASCVD risk [4].

The adult RDA for B6 is 1.3 mg/day for adults aged 19 to 50, rising to 1.5 to 1.7 mg/day for adults over 50, per the National Institutes of Health Office of Dietary Supplements [5].

Homocysteine, B Vitamins, and ASCVD: What the Trials Show

The relationship between B6 supplementation and cardiovascular outcomes is more complicated than the supplement marketing suggests. The NORVIT trial (N=3,749) tested combined folic acid 0.8 mg, B12 0.4 mg, and B6 40 mg daily versus placebo in post-myocardial infarction patients. The B-vitamin combination did not reduce the primary composite endpoint of recurrent MI, stroke, or sudden death; the B6-containing arm showed a non-significant trend toward harm at 3.5 years [6].

The HOPE-2 trial (N=5,522) tested folic acid 2.5 mg plus B12 1 mg plus B6 50 mg daily. After 5 years of follow-up, the B-vitamin group showed no reduction in the primary outcome of cardiovascular death, MI, or stroke (relative risk 0.95, 95% CI 0.84 to 1.07, P=0.41) [7].

These data are relevant to Repatha patients specifically: many people prescribed evolocumab have established ASCVD or familial hypercholesterolemia, the exact populations studied in NORVIT and HOPE-2. High-dose B6 supplementation in that context is not likely to provide additional cardiovascular benefit on top of aggressive LDL-C lowering.

The Upper Limit and Neuropathy Risk

The Tolerable Upper Intake Level (UL) for vitamin B6 is 100 mg/day in adults, established by the National Academies of Medicine [5]. Sustained intake above that threshold, and particularly doses above 200 to 500 mg/day used in some compounding or high-dose supplement regimens, has been associated with sensory peripheral neuropathy characterized by numbness, tingling, and loss of proprioception.

A case series and systematic review published in JAMA found sensory neuropathy with B6 doses as low as 50 mg/day in some patients over prolonged periods, though most cases involved doses above 200 mg/day [8]. Symptoms are generally reversible after discontinuation, but recovery can take months.

Patients on Repatha who also have diabetic neuropathy, renal impairment, or pre-existing peripheral nerve conditions should be especially cautious, since neuropathy symptoms from excess B6 could be mistaken for disease progression.

Drug Interaction Mechanism Analysis: Pharmacokinetic vs. Pharmacodynamic

Pharmacokinetic Pathways: No Overlap

Pharmacokinetic interactions occur when one substance changes the absorption, distribution, metabolism, or excretion of another. Evolocumab has a volume of distribution of approximately 3.3 L based on population pharmacokinetic modeling, consistent with primarily vascular and lymphatic distribution typical of IgG antibodies [2]. It does not rely on intestinal transporters such as P-glycoprotein or organic anion-transporting polypeptides.

Pyridoxine is absorbed in the jejunum via a non-saturable passive diffusion mechanism at physiologic doses. The two compounds share no absorption transporter, no plasma protein binding competition, and no shared renal elimination pathway. The FDA label for evolocumab lists no contraindicated or cautioned co-administrations related to vitamins [2].

Pharmacodynamic Pathways: No Overlap

Pharmacodynamic interactions occur when two agents affect the same biological target or downstream effector, either synergistically or antagonistically. Evolocumab's entire mechanism is confined to inhibiting the PCSK9-LDLR binding interaction at hepatocyte surfaces.

Vitamin B6 coenzyme activity involves aminotransferases, decarboxylases, phosphorylases, and racemases. None of those enzyme families intersect with PCSK9 signaling, LDL receptor expression, or the NPC1L1/ABCG5/ABCG8 cholesterol transport system [9].

The table below summarizes the interaction assessment across four domains:

| Interaction Domain | Mechanism | Evidence of Interaction | Clinical Risk | |---|---|---|---| | CYP450 metabolism | Evolocumab is not a CYP substrate | None | None | | Protein binding displacement | Different binding targets and protein classes | None | None | | PCSK9 pathway antagonism | B6 has no PCSK9 activity | None | None | | Independent toxicity (high-dose B6) | Sensory neuropathy above 100 mg/day | Case reports, systematic reviews | Low to moderate if mega-dosed |

What Doses of B6 Are Acceptable for Someone on Repatha?

Standard Dietary Supplement Doses (Up to 25 mg/day)

Multivitamins typically contain 1.5 to 5 mg of B6. B-complex supplements commonly provide 10 to 25 mg per serving. These doses are well within the National Academies UL of 100 mg/day and present no interaction risk with evolocumab. No dose separation, timing adjustment, or special monitoring is needed in this range [5].

Mid-Range Doses (25 to 100 mg/day)

Some patients take stand-alone B6 in this range for conditions such as premenstrual syndrome (where evidence is modest), carpal tunnel syndrome, or morning sickness during pregnancy. The ACOG Committee Opinion on nausea and vomiting in pregnancy recommends pyridoxine 10 to 25 mg three times daily for pregnancy-related nausea, a total of 30 to 75 mg/day, as a first-line agent [10]. At these doses, still within the 100 mg UL, no interaction with Repatha exists. Long-term use at the upper end of this range merits periodic symptom review for neuropathy.

High Doses Above 100 mg/day

Doses above 100 mg/day should not be taken without a specific clinical indication and physician supervision, regardless of whether the patient is on Repatha. If a prescriber recommends high-dose B6 for a documented deficiency or specific condition (isoniazid co-administration, certain inborn errors of metabolism), the B6 itself does not destabilize evolocumab or reduce its LDL-lowering effect. The concern is entirely the standalone neuropathy risk of pyridoxine excess [8].

Clinical Guidance: What to Tell Your Prescriber

Disclosing Supplements Before Starting Repatha

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states: "Before initiating drug therapy, clinicians should evaluate patients for conditions and lifestyle factors that may worsen hyperlipidemia, including medications and supplements." [11] That means disclosing all supplements, including B6, is part of standard pre-treatment assessment even when the pharmacological interaction risk is zero.

Disclosure matters for a different reason with vitamins: high-dose B vitamin regimens sometimes reflect underlying diagnoses (malabsorption, alcoholism, peripheral neuropathy) that independently affect cardiovascular risk and may change how aggressively a prescriber manages LDL-C targets.

When Neuropathy Symptoms Appear

If a patient on Repatha develops new numbness, tingling, or balance problems, the differential includes B6 toxicity, statin-associated myopathy (though evolocumab is not a statin), diabetic peripheral neuropathy, and other causes. The patient should report these symptoms promptly rather than attributing them to either agent without evaluation.

The FDA MedWatch reporting system accepts supplement-related adverse events, and patients can report unexpected symptoms at FDA Safety Reporting [12].

Reviewing the Full Supplement Panel

Patients on Repatha who take multiple supplements should review the complete list with their prescriber or pharmacist. Red yeast rice, for example, contains monacolin K (lovastatin), a CYP3A4 substrate that introduces statin-related risks even if Repatha itself is interaction-free. Berberine may modestly reduce LDL-C via PCSK9 transcriptional effects and could theoretically produce additive but unmonitored LDL lowering when combined with evolocumab [13]. B6 is among the safest supplements to combine with Repatha, but the same cannot be said for every supplement.

Monitoring Recommendations for Patients Taking Both

Lipid Panel Frequency

The ACC/AHA 2018 guideline recommends a fasting lipid panel 4 to 12 weeks after starting a PCSK9 inhibitor, then every 3 to 12 months [11]. Vitamin B6 supplementation at any standard dose does not alter LDL-C, HDL-C, or triglyceride levels in patients with normal B6 status, so lipid monitoring frequency does not need to change because of B6 use. The HOPE-2 trial confirmed that combined high-dose B vitamins had no effect on lipid fractions at 5 years [7].

Neurological Symptom Surveillance

Any patient taking B6 above 50 mg/day chronically should be asked at each cardiovascular follow-up visit about new-onset tingling, burning, or sensory loss in the hands or feet. This is independent of Repatha use. Plasma pyridoxal-5-phosphate levels can be measured to confirm deficiency or toxicity when symptoms are ambiguous; the normal reference range is approximately 20 to 125 nmol/L [5].

Injection Site and Immunogenicity Monitoring

Evolocumab carries a small risk of injection-site reactions and, rarely, development of anti-drug antibodies. Vitamin supplements, including B6, have no known mechanism for increasing antibody immunogenicity to biologic therapies. The FOURIER and HAUSER-OLE extension studies found stable efficacy and safety over 5 years without dietary supplement-related immunogenicity signals [1][14].

Special Populations

Patients with Familial Hypercholesterolemia

Heterozygous and homozygous FH patients on Repatha typically carry a high baseline cardiovascular risk. The only B6-related concern in this population is avoiding megadose supplementation that could confound neurological exam findings, since FH itself does not cause neuropathy, but xanthoma-related nerve compression occasionally does.

Patients with Chronic Kidney Disease

CKD reduces urinary pyridoxine clearance. Plasma PLP levels may accumulate faster in patients with GFR below 30 mL/min/1.73m2, meaning the practical UL for B6 may be lower in this group [5]. Evolocumab pharmacokinetics are not significantly altered by renal impairment per the prescribing information, but CKD patients on Repatha should apply extra caution before taking B6 above 10 mg/day without nephrology or cardiology input [2].

Pregnant Patients

ACOG endorses pyridoxine for pregnancy nausea at 30 to 75 mg/day [10]. Repatha is classified FDA Pregnancy Category not formally assigned under the newer labeling system, but the prescribing information notes that animal studies at high doses showed no embryofetal harm and that human data are limited [2]. Pregnancy decisions involving both Repatha and B6 require specialist obstetric and cardiology co-management, particularly in FH patients who may continue evolocumab through pregnancy based on individualized risk-benefit analysis.